Stock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline

Stock Track

02-27

Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.

Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.

Analysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1197508058"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197508058\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1197508058?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197508058","market":"hk","top_or_hot":-1,"title":"Stock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline","media":"Stock Track","content":"<p>Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.</p>\n\n<p>Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.</p>\n\n<p>Analysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.</p>\n\n<p>Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.</p>\n\n<p>Analysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1197508058","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197508058","pubTimestamp":1740668778,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Schrodinger Inc.  shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"由于强劲的软件增长和光明的前景超过了收入下降，Schrodinger股价飙升5.39%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SDGR":1},"content_text":"Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.\nDespite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.\nAnalysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}